Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
• Helus Pharma presented new analyses of its HLP003 drug candidate for Major Depressive Disorder at Psych Congress 2026. • The company used poster presentations to detail the clinical profile of HLP003 and its Phase 3 PARADIGM program for adjunctive treatment. • These results provide early data for a potential new treatment option, though the FDA and Health Canada have not yet evaluated or approved the drug's efficacy.
globenewswire.com


